Novo Nordisk, Eli Lilly slide after Trump comments on weight loss drug pricing
NegativeFinancial Markets
Novo Nordisk and Eli Lilly saw their stock prices drop following comments made by former President Trump regarding the pricing of weight loss drugs. Trump's remarks have raised concerns about potential regulatory changes that could impact the profitability of these pharmaceutical companies. This is significant as it highlights the ongoing debate over drug pricing in the U.S. and the potential for political influence on the healthcare market.
— Curated by the World Pulse Now AI Editorial System